Cherchi P L, Marras V, Capobianco G, Ambrosini G, Piga M, Fadda G M, Dessole S
Department of Pharmacology, Gynaecology and Obstetrics, University of Sassari, Italy.
Eur J Gynaecol Oncol. 2001;22(6):433-5.
To assess the immunohistochemical expression of Ber-EP4, a new epithelial antigen in ovarian cancer.
We studied 25 cases of ovarian cancer in which Ber-EP4, CEA and CA 125 were investigated by an immunohistochemical method. We evaluated the correlations between immunohistochemical positivity and grading, histotype and stage of disease.
CEA was positive in 5 out of 25 cases (20%), CA-125 in 17 out of 25 cases (68%) and Ber-EP4 in 14 out of 25 cases (56%). Ber-EP4 was mainly present in mucinous tumors in comparison to serous tumors (78.6% vs. 50%). Ber-EP4, as well as CA-125, were directly proportional to tumor differentation (70% of positivity in G1 vs 37.5% in G3 for the former and 80% in G1 vs 50% in G3 for the latter, respectively), whereas CEA showed no relevant difference regarding the grading. There were no differences among the three antigens studied with regard to clinical stage.
In our study Ber-EP4 was positive in 14 out of 22 cases (63.6%) of the primary epithelial ovarian cancers studied. The presence of this antigen seems to be related to histotype and grading but not to clinical stage.
评估新型上皮抗原Ber-EP4在卵巢癌中的免疫组化表达。
我们研究了25例卵巢癌病例，采用免疫组化方法检测了Ber-EP4、癌胚抗原（CEA）和糖类抗原125（CA 125）。我们评估了免疫组化阳性与疾病分级、组织学类型和分期之间的相关性。
25例病例中5例CEA呈阳性（20%），25例中17例CA-125呈阳性（68%），25例中14例Ber-EP4呈阳性（56%）。与浆液性肿瘤相比，Ber-EP4主要存在于黏液性肿瘤中（78.6%对50%）。Ber-EP4以及CA-125与肿瘤分化呈正比（前者G1期阳性率为70%，G3期为37.5%；后者G1期为80%，G3期为50%），而CEA在分级方面无显著差异。研究的三种抗原在临床分期方面无差异。
在我们的研究中，22例原发性上皮性卵巢癌中有14例（63.6%）Ber-EP4呈阳性。这种抗原的存在似乎与组织学类型和分级有关，而与临床分期无关。
